Scholarlink

Background <p>It remains unclear whether reengaging in lifestyle weight loss interventions is effective for the long-term.</p> Methods <p>We conducted the CENTRAL (trial 1, T1) lifestyle weight-loss trial in 2012–2014, and the DIRECT-PLUS (trial 2, T2) weight-loss trial in 2017–2018. All participants were invited for follow-up in 2022–2024 to assess weight, metabolic biomarkers, and fat depots via magnetic-resonance-imaging (MRI) five years after the second trial.</p> Results <p>The analysis included 572 trial observations contributed by 480 participants; of these, 388 participated in one of the two trials and 92 participated in both (T1 + T2 rejoiners). At follow-up, 384/480 (80%) were re-evaluated, including 76/92 (83%) rejoiners. In T1, participants who participated once and those who later rejoined T2 exhibited similar responses to their first intervention, including comparable weight-loss (-3.3% vs. -3.4%; FDR = 0.93). However, T1 + T2 rejoiners began their second intervention with a similar baseline BMI to their first (31.8&#xa0;kg/m<sup>2</sup> vs. 31.3&#xa0;kg/m<sup>2</sup>; FDR = 0.12). Nevertheless, they presented a more favourable abdominal fat and metabolic profiles at T2 baseline than at their initial T1 baseline (visceral adipose tissue (VAT): 135.5 cm<sup>2</sup> vs. 160.0 cm<sup>2</sup>; homeostatic model assessment of insulin resistance (HOMA-IR): 3.8 vs. 4.5; high density lipoprotein cholesterol (HDL-C)/Triglycerides: 3.6 vs. 4.2; all FDR &lt; 0.05). In response to T2, rejoiners exhibited attenuated improvements compared to those achieved during their previous T1 intervention (weight: -1.5% vs. -3.5%; VAT: -7.2% vs. -33.3%; deep subcutaneous adipose tissue (SAT): -4.0% vs. -31.9%; superficial SAT: -3.3% vs. -25.4%; all FDR &lt; 0.05), and compared to first-time T2 participants (weight: -3.5%; FDR &lt; 0.05, VAT: -11.6%; FDR = 0.20, deep SAT: -9.9%; FDR &lt; 0.05, superficial SAT: -9.3%; FDR = 0.05). Yet, 5&#xa0;years after completing T2, T1 + T2 rejoiners exhibited significantly less weight regain compared with first-time T2 participants (+ 0.2% vs. + 2.9%; FDR &lt; 0.05), deep-SAT regain (+ 2.4% vs. + 13.3%; FDR &lt; 0.05), and superficial-SAT regain (+ 12.8% vs. + 24.3%; FDR &lt; 0.05), though similar VAT regain. Overall, although T1 + T2 rejoiners had higher baseline obesity parameters than first-time participants, they presented comparable values by the 5- and 10-year follow-up.</p> Conclusions <p>Despite an attenuated weight-loss response, repeated engagement in a structured lifestyle intervention yields meaningful long-term impacts with sustainable metabolic benefits.</p> Trial registration <p>CENTRAL (Clinical-trials-identifier:NCT01530724); DIRECT-PLUS (Clinical-trials-identifier:NCT03020186).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

How effective is rejoining a long-term weight loss program? The 5- and 10-year MRI-assessed Follow Interventions Trial (FIT) project

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月30日

查看全文
  • Hadar Klein,
  • Dafna Pachter,
  • Dana Tamar Goldberg Toren,
  • Omer Kamer,
  • Liav Alufer,
  • Noa Ebstein Karamani,
  • Yoash Chassidim,
  • Ilan Shelef,
  • Assaf Rudich,
  • Uri Yoel,
  • Gal Ben-Arie,
  • Hila Zelicha,
  • Anat Yaskolka Meir,
  • Gal Tsaban,
  • Carmi Bartal,
  • Matthias Blüher,
  • Michael Stumvoll,
  • Uta Ceglarek,
  • Berend Isermann,
  • Lu Qi,
  • Meir J. Stampfer,
  • Frank B. Hu,
  • Iris Shai

摘要

Background

It remains unclear whether reengaging in lifestyle weight loss interventions is effective for the long-term.

Methods

We conducted the CENTRAL (trial 1, T1) lifestyle weight-loss trial in 2012–2014, and the DIRECT-PLUS (trial 2, T2) weight-loss trial in 2017–2018. All participants were invited for follow-up in 2022–2024 to assess weight, metabolic biomarkers, and fat depots via magnetic-resonance-imaging (MRI) five years after the second trial.

Results

The analysis included 572 trial observations contributed by 480 participants; of these, 388 participated in one of the two trials and 92 participated in both (T1 + T2 rejoiners). At follow-up, 384/480 (80%) were re-evaluated, including 76/92 (83%) rejoiners. In T1, participants who participated once and those who later rejoined T2 exhibited similar responses to their first intervention, including comparable weight-loss (-3.3% vs. -3.4%; FDR = 0.93). However, T1 + T2 rejoiners began their second intervention with a similar baseline BMI to their first (31.8 kg/m2 vs. 31.3 kg/m2; FDR = 0.12). Nevertheless, they presented a more favourable abdominal fat and metabolic profiles at T2 baseline than at their initial T1 baseline (visceral adipose tissue (VAT): 135.5 cm2 vs. 160.0 cm2; homeostatic model assessment of insulin resistance (HOMA-IR): 3.8 vs. 4.5; high density lipoprotein cholesterol (HDL-C)/Triglycerides: 3.6 vs. 4.2; all FDR < 0.05). In response to T2, rejoiners exhibited attenuated improvements compared to those achieved during their previous T1 intervention (weight: -1.5% vs. -3.5%; VAT: -7.2% vs. -33.3%; deep subcutaneous adipose tissue (SAT): -4.0% vs. -31.9%; superficial SAT: -3.3% vs. -25.4%; all FDR < 0.05), and compared to first-time T2 participants (weight: -3.5%; FDR < 0.05, VAT: -11.6%; FDR = 0.20, deep SAT: -9.9%; FDR < 0.05, superficial SAT: -9.3%; FDR = 0.05). Yet, 5 years after completing T2, T1 + T2 rejoiners exhibited significantly less weight regain compared with first-time T2 participants (+ 0.2% vs. + 2.9%; FDR < 0.05), deep-SAT regain (+ 2.4% vs. + 13.3%; FDR < 0.05), and superficial-SAT regain (+ 12.8% vs. + 24.3%; FDR < 0.05), though similar VAT regain. Overall, although T1 + T2 rejoiners had higher baseline obesity parameters than first-time participants, they presented comparable values by the 5- and 10-year follow-up.

Conclusions

Despite an attenuated weight-loss response, repeated engagement in a structured lifestyle intervention yields meaningful long-term impacts with sustainable metabolic benefits.

Trial registration

CENTRAL (Clinical-trials-identifier:NCT01530724); DIRECT-PLUS (Clinical-trials-identifier:NCT03020186).